palomid 529
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2010 (NCT01033721)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Serine/threonine-protein kinase mTORINHIBITOR
MTOR inhibitor
ATP-competitive mTORC1/mTORC2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(COc2cc3oc(=O)c4cc(C(C)O)ccc4c3cc2OC)cc1- Mol. weight
- 406.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2141712 ↗
Also known as
- p529
- p529
- p-529
- p-529
- palomid 529
- palomid 529
- palomid 529
- palomid-529
- palomid-529
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01271270 | Phase 1 | Dec 20, 2010 | National Eye Institute (NEI) |
| NCT01033721 | Phase 1 | Jun 1, 2010 | Ophthalmic Consultants of Boston, Paloma Pharmaceuticals, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Eye Institute (NEI) | Government | 1 | 1 | 1 | 2010 |
| Ophthalmic Consultants of Boston | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Paloma Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2010 |
3 organizations
Page 1 / 1